Dermata Therapeutics, Inc. (DRMA) AI-Powered Stock Analysis
See how Dermata Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
DRMA●NASDAQ
HealthcareBiotechnology
$1.19
$0.01(0.83%)
U.S. Market opens in 1h 37m
Advertisement
Dermata Therapeutics, Inc. (DRMA)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerDermata Therapeutics, Inc. (DRMA) Stock Overall Grade
Dermata Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Dermata Therapeutics, Inc.'s overall stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
58/100Key Ratios
C+Score
55/100Sector Comparison
C+Score
50/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
C+Score
50/100Dermata Therapeutics, Inc. (DRMA) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (58/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (50/100, C+) indicate weak positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests Low divergence in outlook.Component Analysis Explained
Understand the key factors behind each Dermata Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.